Immunovant Inc (IMVT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Autoimmunesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), 26.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 22.09% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
- Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
- Immunovant (IMVT) Just Gave Investors Something To Think About
- Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
- Lilly’s latest China drug deal; Immunovant’s setback in lupus
- Roivant reports top-line data from IMVT-1402 CLE trial
- Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
- Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). — Front Neurol 2026 PMID 42699831
- Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. — JAMA Neurol 2026 Sep 1 PMID 42545715
- Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy. — Muscle Nerve 2026 Oct PMID 42544732
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. — JAMA Neurol 2026 Sep 1 PMID 42507440
- The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. — Brain Commun 2026 PMID 42500553
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Immunovant Inc.
Full IMVT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.